Sep 16, 2020 / 07:30PM GMT
Albert Hwang;Morgan Stanley;Managing Director -
Good afternoon, everybody. Thank you for joining. This is the FibroGen fireside chat. I'm Albert Hwang from Morgan Stanley. Thanks for being at the conference. And I'd like to introduce the CEO of FibroGen, Enrique Conterno, who -- maybe you can give a couple of minute overview on how things are going with the company. And then we can get started with questions. Enrique?
Enrique A. Conterno - FibroGen, Inc. - CEO & Director
Very good. Thank you, Albert. Thank you very much for the invitation. We have an exciting agenda here at FibroGen. Clearly, roxadustat being commercialized in China and Japan, very much undergoing the final stages of the regulatory review in the United States, submission in Europe. Clearly, a transformational medicine when it comes to CKD anemia.
We are making progress with pamrevlumab on enrollments on a collective of high need medical indications whether it's IPF or LAPC or DMD. So now we basically have Phase III programs in each one of those indications.
FibroGen Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers